---
title: "BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262399890.md"
description: "BOJI CRO's subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained the \"Drug Registration Certificate\" issued by the National Medical Products Administration, approving its production of \"Compound Polyethylene Glycol Electrolyte Powder.\" This drug is used for bowel cleansing prior to endoscopic or radiographic examinations and colon surgeries, with an expected sales scale of approximately RMB 220 million in public hospitals in China in 2024"
datetime: "2025-10-23T10:05:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262399890.md)
  - [en](https://longbridge.com/en/news/262399890.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262399890.md)
---

# BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

BOJI CRO announced that its subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the "Compound Polyethylene Glycol Electrolyte Powder." This drug is suitable for bowel cleansing preparation in adult patients prior to endoscopic or radiological examinations and colon surgeries. According to data from Minet, the sales scale of "Compound Polyethylene Glycol Electrolyte Powder" in public hospitals at the city and county levels in China is approximately 220 million RMB in 2024. The acquisition of the drug registration certificate indicates that the drug has met the relevant national drug review technical standards and can be produced and sold in the domestic market after complying with the requirements of Good Manufacturing Practice

### Related Stocks

- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [16:51 ETSun Home Luminar Named Best Overall Outdoor Sauna of 2026 in homesauna.com Buyer's Guide](https://longbridge.com/en/news/286818113.md)